UBS Group
RGNX icon

UBS Group’s Regenxbio RGNX Stock Holding History

UBS Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49,300
Closed -$885K – 9905
2023
Q4 		$885K Hold
49,300
– – ﹤0.01% 4610
2023
Q3 		$811K Hold
49,300
– – ﹤0.01% 4272
2023
Q2 		$986K Buy
+49,300
New +$950K ﹤0.01% 4257
2021
Q4 		– Sell
-41,338
Closed -$1.73M – 10628
2021
Q3 		$1.73M Buy
+41,338
New +$1.49M ﹤0.01% 3696
2018
Q4 		– Sell
-500
Closed -$38K – 8246
2018
Q3 		$38K Hold
500
– – ﹤0.01% 6375
2018
Q2 		$36K Buy
+500
New +$23.9K ﹤0.01% 6257

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return